Amylyx Pharmaceuticals, Inc.
AMLXHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 23, 2026
Scan Results
Daily timeframeAmylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the. At a $3.59B market cap, Amylyx Pharmaceuticals, Inc. ranks as a mid-cap company within healthcare. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
Market Cap
$3.59B
Beta
-0.09
P/E (TTM)
—
P/E (Fwd)
-26.20
EPS (TTM)
$-1.39
EPS (Fwd)
$-1.09
ROE
-74.7%
ROA
-44.1%
Cash
$250.8M
Total Debt
$5.3M
Free CF
-$77.3M
52W Change
99.7%
Annual Financials
Cash vs Debt
Where AMLX stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, AMLX finished 25.43% above its 150-day moving average ($21.00) and 36.62% above its 200-day moving average ($19.28). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AMLX overbought or oversold?
At the October 19, 2026 close, AMLX's RSI(14) was 26.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $250.8M in cash and $5.3M in debt, AMLX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$77.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -74.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $22.2M (2022) to $0 (2025), a 100% decline worth watching.
With a beta below 0.7, Amylyx Pharmaceuticals, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing AMLX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.